Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VIR 2218

Drug Profile

VIR 2218

Alternative Names: ALN-HBV02; BRII-835; VIR-2218

Latest Information Update: 23 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Developer Alnylam Pharmaceuticals; Brii Biosciences; Vir Biotechnology
  • Class Antivirals; Small interfering RNA
  • Mechanism of Action Hepatitis B surface antigen expression inhibitors; RNA interference; Viral protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis B

Most Recent Events

  • 12 Nov 2021 Efficacy and safety data from a phase II trial in Hepatitis B presented at the American Association for the Study of Liver Diseases The Liver Meeting® (AASLD-2021)
  • 30 Sep 2021 Vir Biotechnology, Alnylam Pharmaceuticals and Brii Biosciences completes a phase II trial in Hepatitis B (Monotherapy) in China (SC) (NCT04507269)
  • 15 Jul 2021 Phase-II clinical trials in Hepatitis B (Combination therapy) in United Kingdom, Ukraine, Malaysia (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top